Medicare Formulary Rules Add Bite to "Black Box" Warnings
This article was originally published in RPM Report
Executive Summary
CMS is sharply limiting the ability of Medicare plans to make formulary changes during a plan year-except when FDA demands a new warning. Though CMS says it doesn't want to interfere with FDA's regulation of drug safety, the policy is likely to complicate the already difficult labeling negotiations over new warnings.
You may also be interested in...
The Threat of Reconciliation: Remembering the Part D Vote
Democrats are threatening to use a budgetary procedure to accelerate the passage of broad health reforms in the next Congress. Republicans are already voicing protest, particularly with the idea of a new government-run insurance plan gaining momentum. But those concerns may fall on deaf ears.
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
CMS’ coverage policy on erythropoietin has huge commercial implications for Amgen and J&J. It is also a wake-up call for the rest of the industry: there are now two regulators who control the keys to success in the pharmaceutical industry.
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
CMS’ coverage policy on erythropoietin has huge commercial implications for Amgen and J&J. It is also a wake-up call for the rest of the industry: there are now two regulators who control the keys to success in the pharmaceutical industry.